FDA 483 - Neilmed Pharmaceuticals Inc - December 02, 2022

An FDA inspection conducted at Neilmed Pharmaceuticals Inc. from November 28 to December 2, 2022, uncovered significant lapses in the company's drug manufacturing and quality control systems, resulting in a Form FDA 483. The primary concerns highlight a lack of an independent and effective quality control unit and non-compliance with Good Manufacturing Practices.

Key issues included deficient investigations into customer complaints, often lacking root cause analysis and proper documentation. Equipment cleaning verification was inadequate, with missing logs and visible residue in supposedly cleaned tanks. A critical observation was the lack of separation between quality and production departments, where manufacturing staff performed essential product release testing without sufficient quality oversight or record review. The firm also failed to conduct reviews of retained drug product samples, used non-pharmaceutical grade reagents without justification, and lacked proper verification for in-process testing equipment. Additionally, there was a failure to demonstrate adequate training for personnel performing release testing.

Further deficiencies involved the absence of established responsibilities for investigating out-of-specification results from an unregistered contract testing laboratory whose methods were unverified. Raw material testing, specifically for Glycerin, was inadequate, missing critical identity tests and impurity monitoring. Improper storage conditions for raw materials, without a documented warehouse temperature mapping study, also posed a risk. Finally, the company failed to document production deviations and accurately reconcile rejected products, hindering effective problem resolution.

Under the Federal Food, Drug, and Cosmetic Act, Neilmed Pharmaceuticals Inc. is required to address these observations by implementing comprehensive corrective and preventive actions to ensure product quality, safety, and regulatory compliance. This includes establishing a robust and independent quality system, validating processes, improving documentation practices, and ensuring adequate personnel training.